CARE - Quality Improvement in Cardiovascular Secondary Prevention in Primary Care, Through Delegation of Consultations to the Nurse.

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00713960
First received: July 10, 2008
Last updated: January 13, 2012
Last verified: January 2012
  Purpose

Quality Improvement in Primary Care: delegation of check-ups to nurses in general practice


Condition
Cardiovascular Disease

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: CARE - Quality Development in Cardiovascular Disease in General Practice

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Cholesterol, HDL -cholesterol, LDL-Cholesterol, Blood pressure, Exercise, Waist-circumference, BMI, Smoking status, fasting plasma-glucose, medication taken [ Time Frame: As needed, min. baseline and after 6 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Number of visits pr. patients, drop-out [ Time Frame: Annually ] [ Designated as safety issue: No ]

Enrollment: 2193
Study Start Date: April 2008
Study Completion Date: December 2010
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
Patients in secondary prevention of cardiovascular disease in primary care

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Primary care clinic

Criteria

Inclusion Criteria:

  • Patients in secondary prevention of cardiopathy (ischaemic heart disease, claudication intermittence, thrombotic apoplexy cerebri, diabetes) who are not followed in an outpatient department.

Exclusion Criteria:

  • Patients who suffer from diabetic nephropathy will be excluded
  • According to the general practitioners appraisal, patients who suffer from severe co morbidity can be excluded as well.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00713960

  Show 66 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Study Chair: Henrik Ommen, MD Lægerne i Løgumkloster I/S, Denmark
Study Chair: Dorte Knudsen Lægerne Sønderåparken, Denmark
  More Information

No publications provided

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT00713960     History of Changes
Other Study ID Numbers: NIS-CDK-DUM-2008/1
Study First Received: July 10, 2008
Last Updated: January 13, 2012
Health Authority: Denmark: Danish Dataprotection Agency

Keywords provided by AstraZeneca:
Quality development project
primary care nurses
cardiovascular disease
secondary prevention
follow-up

Additional relevant MeSH terms:
Cardiovascular Diseases

ClinicalTrials.gov processed this record on August 21, 2014